<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52110">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02107430</url>
  </required_header>
  <id_info>
    <org_study_id>SP004</org_study_id>
    <secondary_id>2011-004967-65</secondary_id>
    <nct_id>NCT02107430</nct_id>
  </id_info>
  <brief_title>Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer</brief_title>
  <official_title>Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Patients With Localized High-risk Prostate Cancer After Primary Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotio a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotio a.s.</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DCVAC/PCa added after radical primary
      prostatectomy can improve PSA progression times within 5 years for patients with high risk
      localized Prostate Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment post radical primary prostatectomy Treatment post standard radiotherapy
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Prostate Specific Antigen (PSA) failures in 5 years</measure>
    <time_frame>260 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients without use of salvage therapy  within 5 years</measure>
    <time_frame>260 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>0, 2, 11, 13, 17, 21, 25, 29, 33, 37, 41, 45, 57, 69, 81, 93, 105, 166, 218, 260 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients without Objective disease progression within 5 years</measure>
    <time_frame>260 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>DCVAC/PCa arm post radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCVAC/PCa Experimental therapy post radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/PCa</intervention_name>
    <description>DCVAC/PCa arm post radiotherapy</description>
    <arm_group_label>DCVAC/PCa arm post radiotherapy</arm_group_label>
    <arm_group_label>Standard radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard radiotherapy</intervention_name>
    <description>radiotherapy</description>
    <arm_group_label>Standard radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male 18 years and older

          -  Histologically confirmed localized prostate cancer of high risk or very high risk
             fulfilling at least one of the following: T3-T4 stage or Gleason Score 8-10 or PSA
             level above 20 ng/ml

          -  Indication for prostate cancer radical radiotherapy

          -  Neo-adjuvant androgen androgen-deprivation therapy due to prostate cancer using
             Luteinizing-hormone-releasing hormone (LHRH) analogues ongoing for at least two
             months and not longer than 12 months prior randomization

          -  Eastern Cooperative Oncology Group (ECOG)  0-2

        Exclusion Criteria:

          -  Primary surgical treatment of prostate cancer

          -  Prior or ongoing chemotherapy for prostate cancer

          -  Participation in other clinical study or administration of other evaluated drug
             within 30 day prior screening

          -  Unresolved lasting obstruction of urinary system

          -  Other uncontrolled inter-current illness

          -  Treatment with immunotherapy against Prostate Cancer

          -  Clinically significant cardiovascular disease

          -  History of primary immunodeficiency

          -  Active autoimmune disease requiring treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jihlava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novy Jicin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 8</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Prostate Cancer (PCa)</keyword>
  <keyword>Biological, Vaccine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
